Vitamin D: beyond bone. by Christakos, Sylvia et al.
UCSF
UC San Francisco Previously Published Works
Title
Vitamin D: beyond bone.
Permalink
https://escholarship.org/uc/item/3f97443q
Journal
Annals of the New York Academy of Sciences, 1287(1)
ISSN
0077-8923
Authors
Christakos, Sylvia
Hewison, Martin
Gardner, David G
et al.
Publication Date
2013-05-17
DOI
10.1111/nyas.12129
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Ann. N.Y. Acad. Sci. ISSN 0077-8923
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Issue: Annals Meeting Reports
Vitamin D: beyond bone
Sylvia Christakos,1 Martin Hewison,2 David G. Gardner,3 Carol L. Wagner,4 Igor N. Sergeev,5
Erica Rutten,6 Anastassios G. Pittas,7 Ricardo Boland,8 Luigi Ferrucci,9 and Daniel D. Bikle10
1Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, Newark, New Jersey. 2Department
of Orthopedic Surgery, The David Geffen School of Medicine at the University of California, Los Angeles, California. 3Diabetes
Center and Department of Medicine, University of California, San Francisco, California. 4Division of Neonatology, Department
of Pediatrics, Medical University of South Carolina, Charleston, South Carolina. 5Department of Health and Nutritional
Sciences, South Dakota State University, Brookings, South Dakota. 6Ciro, Center of Expertise for Chronic Organ Failure, Horn,
the Netherlands. 7Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts.
8Departamento de Biologı´a, Bioquı´mica, y Farmacia, Universidad Nacional del Sur, Bahia Blanca, Argentina. 9Longitudinal
Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, Maryland. 10Departments of Medicine
and Dermatology, University of California San Francisco, and VA Medical Center, San Francisco, California
Address for correspondence: annals@nyas.org
In recent years, vitamin D has been received increased attention due to the resurgence of vitamin D deficiency and
rickets in developed countries and the identification of extraskeletal effects of vitamin D, suggesting unexpected
benefits of vitamin D in health and disease, beyond bone health. The possibility of extraskeletal effects of vitamin
D was first noted with the discovery of the vitamin D receptor (VDR) in tissues and cells that are not involved
in maintaining mineral homeostasis and bone health, including skin, placenta, pancreas, breast, prostate and colon
cancer cells, and activatedT cells. However, the biological significance of the expression of theVDR in different tissues
is not fully understood, and the role of vitamin D in extraskeletal health has been a matter of debate. This report
summarizes recent research on the roles for vitaminD in cancer, immunity and autoimmune diseases, cardiovascular
and respiratory health, pregnancy, obesity, erythropoiesis, diabetes, muscle function, and aging.
Keywords: vitamin D; cancer; immunity; pregnancy; obesity; diabetes; pulmonary disease; muscle; aging; cognitive
function
Introduction
Traditionally, vitaminDhas been considered almost
exclusively in the context of its role in calciumhome-
ostasis. Vitamin D can either be taken in the diet,
largely though fortification of dairy products, or
synthesized in the skin from 7-dehydrocholesterol
upon exposure to UV irradiation.Whether ingested
or synthesized, vitamin D is transported to the liver,
where it is hydroxylated at position 25 to form
25-hydroxyvitamin D (25(OH)D2 or 25(OH)D3),
the major circulating form of vitamin D. Next,
25(OH)D3 is transported to the kidney, where it is
hydroxylated at position 1 by the enzyme CYP27B1
to form 1,25-dihydroxyvitamin D (1,25(OH)2D3),
the most active form of vitamin D, which is then
transported to target tissues, where it functions like
a steroid, binding to the vitamin D receptor (VDR).
The VDR heterodimerizes with the retinoid X re-
ceptor (RXR), and the VDR/RXR complex binds to
VDR-responsive elements found in or around target
genes and, in association with various co-activators,
results in the transcription of target genes. When
there is a need to increase blood calcium levels (e.g.,
during growth or pregnancy), 1,25(OH)2D3 acts in
the intestine to increase calcium absorption. If this
increased intestinal absorption is insufficient to re-
store normal calcium levels, 1,25(OH)2D3 works in
concert with the parathyroid hormone (PTH) in
the kidney to promote calcium reabsorption from
the distal tube, and in the skeletal system to release
calcium from bones.
While it was long held that vitamin D acted
only at the intestine, kidney, and skeleton, and
that its function was limited to calcium homeosta-
sis, the possibility of extraskeletal effects has been
doi: 10.1111/nyas.12129
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considered for decades as a result of the discovery
of the VDR in tissues that have no involvement in
calcium homeostasis (e.g., skin, placenta, pancreas,
breast, prostate and colon cancer cells, and activated
Tcells).Discoveryof theVDRandCYP27B1 in these
tissues led to exploration of the roles and mecha-
nisms of vitamin D function in each. On September
21, 2012, the Abbott Nutrition Health Institute and
the Sackler Institute for Nutrition Science at the
New York Academy of Sciences sponsored a con-
ference, “Vitamin D: Beyond Bone,” that gathered
researchers investigating vitamin D in a wide range
of tissues and diseases.
Nonclassical effects of vitamin D
Vitamin D: beyond bone
Sylvia Christakos (UMDNJ-New Jersey Medical
School) began the meeting by summarizing the
metabolism and activity of vitaminD and introduc-
ing the emerging awareness of roles for vitamin D
beyond calcium homeostasis and bonemetabolism.
Evidence in the laboratory, including the use of ani-
malmodels, indicates that 1,25(OH)2D3 generates a
number of extraskeletal effects, including inhibition
of cancer progression, effects on the cardiovascular
system and skin, modulation of innate immunity
with subsequent killing of bacteria, and inhibition
of certain autoimmune diseases (reviewed in
Ref. 1). For example, in rats treated with the chem-
ical carcinogen N-methyl N-nitrosourea (NMU),
1,25(OH)2D3 inhibits the progression of breast
tumors. In addition, when 1,25(OH)2D3 is given
prior to NMU, tumor incidence is prevented or
reduced.1 1,25(OH)2D3 also reduces the incidence
and severity of prostate neoplasia in a mouse model
(Ndx 3.1; Pten mutant mouse), and 1,25(OH)2D3
has tumor inhibitory activity in a mouse model of
colorectal adenoma (Apcmin). In order to determine
mechanisms involved in inhibition of breast tumor
growth, Christakos’ lab showed that C/EBP, a
transcription factor that has been shown to play
a critical role in growth arrest of other cell types,
is induced by 1,25(OH)2D3 in MCF-7 human
breast cancer cells.2 C/EBP was found to induce
transcription of the vitamin D receptor in MCF-7
cells.2 Since the levels of the VDR correlate with the
antiproliferative effects of 1,25(OH)2D3, and since
it has been suggested that C/EBP can be consid-
ered a potential tumor suppressor, these findings
suggest mechanisms whereby 1,25(OH)2D3 may
act to inhibit growth of breast cancer cells. These
findings also identify C/EBP as a 1,25(OH)2D3
target in breast cancer cells and provide evidence for
C/EBP as a candidate for breast cancer treatment.2
With regard to autoimmune diseases,
1,25(OH)2D3 has been shown to suppress type 1
diabetes in the non-obese diabetic (NOD) mouse
model, to suppress experimental autoimmune en-
cephalomyelitis (EAE) (a mouse model of multiple
sclerosis (MS)), and to suppress mouse models of
inflammatory bowel disease and systemic lupus
erythematosus.1 Recent studies from Christakos’
lab have shown that inhibition of EAE is associated
with inhibition of interleukin (IL)-17, a cytokine
that plays a critical role in numerous inflammatory
conditions and autoimmune diseases including
MS. The mechanism of 1,25(OH)2D3 suppression
of IL-17 was found to be transcriptional and to
involve blocking of nuclear factor for activated
T cells (NFAT, which is important for T cell
receptor–mediated transcriptional regulation of
IL-17), recruitment of histone deacetylase to the
IL-17 promoter, and sequestration of Runt-related
transcription factor 1 (Runx1) by the VDR.3
1,25(OH)2D3 was also found to have a direct
effect on the induction of Foxp3, a transcription
factor that associates with NFAT and Runx1 for
transcriptional repression.3 These results describe
novel mechanisms and new concepts with regard
to vitamin D and the immune system and suggest
therapeutic targets for the control of autoimmune
diseases.
Unlike the association between vitamin D defi-
ciency and rickets, causal links between vitamin D
deficiency and specific extraskeletal diseases have yet
to be identified. However, the evidence in the labo-
ratory of beneficial effects of 1,25(OH)2D3 beyond
bone is compelling (summarized in Fig. 1). Findings
in animal models may suggest mechanisms involv-
ing similar pathways in humans that could lead to
the identification of new therapies.
Vitamin D in immune function and disease
prevention
Martin Hewison (the David Geffen School of
Medicine, University of California) detailed one of
the most prominent of the so-called nonclassical
effects of vitamin D: its ability to act as a potent
modulator of human immune responses. Evidence
for this initially stemmed from two observations.
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Figure 1. Genomicmechanismof vitaminDaction.Mechanismof actionof 1,25(OH)2D3 in target cells. TheVDRheterodimerizes
with the RXR. After interaction with the VDRE (vitamin D response element), transcription proceeds through the interaction of
the VDRwith coactivators and with the transcriptionmachinery. The histone acetyltransferase (HAT) activity–containing complex
(SRC/p160andCBP), theDRIPcomplex, andadditional coactivatorsnot shown(including specificmethyltransferases) are recruited
by liganded VDR. 1,25(OH)2D3 is known to maintain calcium homeostasis and to affect numerous other cell types. Effects on
other cell systems, including modulation of the immune system and inhibition of proliferation of cancer cells, are discussed. With
permission from Christakos.60
First, many cells from both the innate and adaptive
immune systems express the VDR. Second, antigen
cells from the innate immune system, such as
macrophages or dendritic cells (DCs), also express
the vitamin D activation enzyme 1-hydroxylase,
also known as CYP27B1. As such, these cells
are able to convert precursor 25(OH)D3, the
major circulating form of vitamin D, to active
1,25(OH)2D3 that can then induce responses in
the cells by binding to their VDRs and promoting
transcriptional regulation.
This localized intracrine mechanism appears to
be central to two key features of immune func-
tion: innate antibacterial activity and the presen-
tation of antigen to cells from the adaptive immune
system such as T lymphocytes (T cells). In
macrophages and monocytes, cellular sensing of
pathogens, such as Mycobacterium tuberculosis, by
pattern recognition receptors, such as Toll-like re-
ceptors, enhances expression of CYP27B1 and the
VDR, thereby increasing intracrine synthesis and
activity of 1,25(OH)2D3.4 The resulting effects, in-
cluding enhanced expression of the antibacterial
proteins cathelicidin and -defensin 2, and en-
hanced formation of autophagosomes, facilitate im-
proved bacterial killing in a vitamin D–dependent
fashion. Vitamin D insufficiency or deficiency may
therefore impair innate immune responses and pre-
dispose individuals to infection, and low serum
concentrations of 25(OH)D3 have been linked to
infectious diseases such as tuberculosis. However,
it is important to recognize that similar antibac-
terial responses to vitamin D have also been re-
ported for other cell types within tissues, such as
the skin, lungs, GI tract, and placenta, that may
broadly be termed barrier sites. Thus, it is possible
that vitamin D deficiency has a generalized detri-
mental impact on antibacterial responses and may
therefore play a role in many types of infectious
diseases.5 An important note by Hewison is that
current data suggest that this particular immune
response to vitamin D is restricted to primates,
underlining a potential role for vitamin D in the
evolution of primate immunity, but also limiting
the scope of further in vivo studies to explore this
activity.
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The immunomodulatory effects of vitamin D
also involve the adaptive immune system. Intracrine
synthesis of 1,25(OH)2D3 by DCs decreases their
maturation, thereby suppressing antigen presen-
tation and decreasing T cell proliferation.6 Re-
cent studies have shown that intracrine expression
and activity of CYP27B1 by DCs is particularly
effective in supporting the generation of tolero-
genic regulatory T (Treg) cells, while simultaneously
suppressing inflammatory IL-17–expressing T cells
(Th17 cells).7 In this way, localized metabolism
of 25(OH)D3 may play a pivotal role in preven-
tion and/or treatment of autoimmunediseases, such
as multiple sclerosis, rheumatoid arthritis, and in-
flammatory bowel disease. As with antibacterial
responses to infection, it has been proposed that
adaptive immune responses may be compromised
in patients with low serum concentrations of
25(OH)D3, and association studies have shown
links between autoimmune disease and vitamin D
deficiency. The extent towhich vitaminDdeficiency
is a cause of immune disease has yet to be demon-
strated and will require new prospective clinical tri-
als of vitamin D supplementation. Hewison stated
that it will be important to definewhether enhanced
vitamin D–mediated immunity prevents immune
disease or whether it can be used as therapy for
these diseases. Moreover, it is possible that some
diseases, such as leprosy and HIV infection, may be
associated with dysregulation of the core vitamin
D intracrine immune mechanism, and may there-
fore require higher circulating levels of 25(OH)D3
to reestablish normal immune responses. These and
other facets of vitamin D and immune function will
be important research challenges for the vitamin D
community.
Vitamin D in the heart and vascular system
David G. Gardner (University of California, San
Francisco) expanded the discussion of nonclassi-
cal effects of vitamin D to include evidence of a
significant role for vitamin D in the cardiovascular
system. While the heart and vasculature have only
recently been identified as potential targets of vita-
min D action, a growing body of evidence suggests
that the activated VDR plays an important role in
regulating cardiovascular function.8 First, the VDR
and the ligand-generating 25-hydroxyvitamin D3
1--hydroxylase have been shown to be present
in cardiac myocytes, cardiac fibroblasts, vascular
smooth muscle cells, and vascular endothelial cells.
Second, vitamin D deficiency in rodents has been
shown to elicit increases in blood pressure and
cardiac hypertrophy. Third, 1,25(OH)2D3 and its
analogs have been shown to reverse agonist-induced
myocyte hypertrophy in vitro and endogenous car-
diac hypertrophy in the Dahl S rat, the sponta-
neous hypertensive rat (SHR), the spontaneous hy-
pertensive heart failure–prone rat (SHR-HF), and
the 5/6 nephrectomymodel of chronic renal failure,
in vivo. Fourth, a variety of cardiovascular disorders
including congestive heart failure, coronary artery
disease, and peripheral vascular disease have been
linked to reduced circulating levels of 25(OH)D3.
Fifth, and perhaps most important, a mouse with a
complete deletion of the VDR gene demonstrates
both hyperreninemic hypertension and cardiac
hypertrophy.9
Gardner and colleagues examined the ability of
paricalcitol, a bioactive analog of 1,25(OH)2D3, to
prevent cardiac hypertrophy in rats infused with
moderate doses of angiotensin II (800 ng/kg/min)
over a 14-day period. Infusion of angiotensin II led
to increased blood pressure, increased myocyte hy-
pertrophy, increased expression of the hypertrophy-
sensitive fetal gene program (i.e., atrial natriuretic
peptide, B-type natriuretic peptide, and alpha skele-
tal actin gene expression), and increased cardiac in-
terstitial fibrosis with augmented procollagen 1 and
3 expression. In each case, coadministration of pari-
calcitol (intraperitoneal injection of 300 ng/kg every
48 h), resulted in partial reversal of the angiotensin
II effects.10
In an effort to define the role of the VDR in
the myocardium, Gardner and colleagues created a
mouse with a selective deletion of the fourth exon
of the murine Vdr gene in cardiac myocytes. This
mouse displayed an increase in myocyte size, left
ventricular weight/body weight, and hypertrophy-
dependent fetal gene expression compared with
control littermates. There was no demonstrable
increase in interstitial fibrosis. The mouse also
demonstrated a reduction in end-diastolic and
end-systolic volume by echocardiography and
increased expression of modulatory calcineurin
inhibitory protein 1 (MCIP1), a direct downstream
target of calcineurin and NFAT that has been linked
to the development of cardiac hypertrophy. Gard-
ner’s group showed that isoproterenol treatment
of neonatal rat cardiac myocytes in vitro resulted
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in myocyte hypertrophy and increased MCIP1
expression. Coadministration of 1,25(OH)2D3
resulted in a dose-dependent reduction in MCIP1
expression.11
Vitamin D and the VDR have also been impli-
cated in the support of normal endothelial func-
tion. Endothelial dysfunction, regarded by many
as a harbinger of cardiovascular disease, has been
linked to a number of disorders that are also asso-
ciated with low circulating levels of 25(OH)D3. In
some cases, treatment of these disorders with exoge-
nous vitamin D or vitamin D metabolites has been
shown to restore endothelial function. To establish
a link between the VDR and endothelial function,
Gardner and colleagues created a mouse with selec-
tive deletion of the Vdr gene in vascular endothe-
lial cells. This mouse displays many of the pheno-
typic features normally associated with endothelial
dysfunction.
Collectively, these data demonstrate that the vi-
tamin D system—specifically, the ligand-bound
VDR—plays an important role in the maintenance
of cardiovascular health and suggest that vitamin D
repletion may have important public health impli-
cations in controlling the prevalence of, and mor-
bidity associated with, cardiovascular disease. Of
equivalent importance, therapy with high potency
vitamin D metabolites or their analogs may sub-
serve an important role in the management of these
diseases.
Vitamin D during pregnancy and lactation
Vitamin D as a preprohormone has effects that ex-
tend beyond calcium metabolism and homeosta-
sis throughout life but which are most vivid dur-
ing pregnancy when vitamin D metabolism is dis-
engaged from its usual constraints.12 At no other
time during the lifecycle is 25(OH)D3 linked di-
rectly to 1,25(OH)2D3 production, the latter rising
more than 2.5 times above nonpregnant levels.12
This elevation of 1,25(OH)2D3 likely serves the pur-
pose of immune regulation, though there have been
only a few studies that have evaluated the effect of
vitamin D status on immune function during preg-
nancy to support this hypothesis. In addition, few
randomized controlled trials have been conducted
in pregnant women to determine optimal vitamin
D status.13–15
Carol L. Wagner (Medical University of South
Carolina) discussed two recent studies performed
by her group in collaboration with Bruce Hol-
lis’s group—the National Institute of Child Health
and Human Development (NICHD) Vitamin D
Pregnancy Trial12 and the Thrasher Research Fund
Vitamin D Community-Based Supplementation
Trial16—that indicate that 400 IU vitamin D, the
amount found in most prenatal vitamins, is inad-
equate and that 4000 IU/day is necessary to op-
timize 1,25(OH)2D3 production, achieved when
total circulating 25(OH)D3 is at least 40 ng/mL
(Fig. 1).12 When analyzed by maternal 25(OH)D3
concentration at various time points—i.e., baseline,
by trimester, throughout pregnancy as mean, me-
dian, and area under the curve, or at delivery—
the group taking 4000 IU/day attained optimal
1,25(OH)2D3 conversion from 25(OH)D3 through-
out pregnancy at considerably higher rates than
groups taking lower doses. Both studies provide
evidence that 4000 IU/day is not only safe but is
associated with fewer adverse events of pregnancy
when taken together as comorbidities of pregnancy,
compared with the lower dose groups.
Comorbidities of pregnancy appear to be directly
linked to lower 25(OH)D3, and, conversely, increas-
ing 25(OH)D3 appears to afford protection to the
mother and developing fetus, with lower risk of
preterm labor, preterm birth, or infection for each
10 ng/mL increase in total circulating 25(OH)D3
concentration.16 Such findings suggest a simple ap-
proach to reducemorbidities during pregnancy. Yet,
before such findings are fully embraced, the mech-
anism(s) of action of vitamin D and its protective
effect during pregnancy must be better delineated.
Additional research that addresses the impact of vi-
taminD on immune homeostasis during pregnancy
and its effects during early infancy and later child-
hood becomes essential.
These findings extend to lactation and early in-
fancy. It was thought for decades that human milk
was minimally sufficient in vitamin D;17 yet, pre-
liminary results of the recently completed NICHD
vitamin D supplementation trial during lactation
show that when a mother is vitamin D replete, with
an intake of 6400 IU vitamin D3/day, breast milk
is replete and a breastfeeding infant has excellent
vitamin D status without infant supplementation
that is comparable to combined maternal and in-
fant supplementation of 400 IU vitamin D3/day.18
The implications of safely achieving vitamin D suf-
ficiency for both mother and breastfeeding infant
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solely throughmaternal supplementation is just be-
ginning to be understood and will likely challenge
researchers for decades to come.
Vitamin D and obesity
Igor N. Sergeev (South Dakota State University)
discussed the possibility of integrating vitamin D
supplementation with current strategies in the pre-
vention and treatment of obesity. The induction of
adipocyte death through apoptosis is emerging as
a promising strategy for addressing obesity.19, 20 In-
creased adipose tissue mass is the result of both
hypertrophy (an increase in adipocyte size) and hy-
perplasia (an increase in adipocyte number), and
once adipocytes achieve a maximum size, further
increase in adipose tissue mass involves an increase
in adipocyte number. Thus, weight loss can result
from not only a decrease in adipocyte size but also
adipocyte number. Even a small increase in the
amount of adipocyte apoptosis will prevent exces-
sive accumulation of adipose tissue and can result
in a significant loss of adipose tissuemass over time.
Therefore, removal of adipocytes through apopto-
sis reduces body fat and can help in long-lasting
maintenance of weight loss.
The effects of the hormonal form of vitamin
D, 1,25(OH)2D3, on apoptotic cell death are
mediated via multiple signaling pathways that
involve common regulators and effectors converg-
ing on cellular Ca2+.19, 21 Sergeev and colleagues
have shown that the critical characteristic of the
apoptotic Ca2+ signal is a sustained increase in
the concentration of intracellular Ca2+, reaching
elevated but not cytotoxic levels.22 However,
1,25(OH)2D3-regulated, Ca2+-dependent apop-
totic molecular targets have not been identified
in adipose tissue. Thus, Sergeev and colleagues
have been investigating the mechanism by which
1,25(OH)2D3 regulates apoptosis in adipocytes.
Their results have demonstrated that 1,25(OH)2D3
induces, in a concentration- and time-dependent
fashion, a sustained, prolonged increase in concen-
tration of intracellular Ca2+ (the apoptotic Ca2+
signal) in mature mouse 3T3-L1 adipocytes.23 The
1,25(OH)2D3-induced increase in cellular Ca2+
is associated with activation of Ca2+-dependent
-calpain and Ca2+/calpain-dependent caspase-
12.23 Activation of these proteases is sufficient to
effect morphological and biochemical changes con-
sistent with apoptosis. The 1,25(OH)2D3-induced
Figure 2. Body-weight gain in mice fed high-fat diets with
increased levels of Ca and vitamin D. Weight matched mice
were randomly assigned to the experimental high-fat (HF) diets
containing 60% energy as fat (the normal control diet contained
10% energy as fat). The treatment groups onHF diet were high-
calcium (Ca diet, 1.2% Ca), high-vitamin D3 (D diet; vitamin
D3 intake 10 times higher than the recommended level of 1000
IU/kg) and high-Ca plus high-D3 (Ca+Ddiet). Data aremeans
for each group and time point; n= 7–8 per group fromweek 1 to
week 10.The insert shows (from left to right)mice from theDIO,
control, and Ca + D groups at week 10. Data are unpublished
and from work in progress.
increase in cellular Ca2+ is also associated with
reduced lipid accumulation in mature adipocytes.23
In prelimary but ongoing studies, a murine
diet-induced obesity (DIO) model is being used to
evaluate the role of vitaminD in adiposity.DIOmice
(C57BL/6J) fed a high-vitaminD3 diet, in particular
a high-vitamin D3 plus high-calcium diet, show
decreased body and fat weight gain (Fig. 2; unpub-
lished data) and improvedmarkers of adiposity and
vitaminD status (plasma concentrations of glucose,
insulin, adiponectin, 25(OH)D3, 1,25(OH)2D3, and
PTH), but an increased plasma Ca2+. High vitamin
D3 and calcium intake is associated with activation
of the Ca2+-dependent apoptotic proteases calpain
and caspase-12 in adipose tissue of DIOmice. These
preliminary findings suggest that the 1,25(OH)2D3-
induced cellular Ca2+ signal can act as an apoptotic
initiator that directly recruits Ca2+-dependent
apoptotic effectors capable of executing apoptosis in
adipose tissue. The preliminary results also suggest
that high vitamin D and calcium intake decreases
body and fat weight gain in diet-induced obesity,
and that the potential mechanism of these effects
involves activation of a Ca2+-mediated apoptotic
pathway in adipose tissue (specifically, normal-
ization of the activities of apoptotic proteases
50 Ann. N.Y. Acad. Sci. 1287 (2013) 45–58 C© 2013 New York Academy of Sciences.
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Ca2+-dependent calpain and Ca2+/calpain-
dependent caspase-12 that are reduced in obesity).
Targeting Ca2+ signaling and the vitamin D/Ca2+–
dependent calpains and caspases in adipocytes with
vitamin D supplementation may therefore be an
effective and affordable approach for chemopreven-
tion and treatment of obesity. Additional studies
are warranted to evaluate this approach from a
safety point of view and to identify the optimal
levels of calcium and vitamin D intakes in obesity.
Vitamin D and lung function in patients with
chronic obstructive pulmonary disease
EricaRutten (Ciro+,CentreofExpertise forChronic
Organ Failure, Netherlands) discussed her work in-
vestigating the association between plasma vitamin
D levels and lung function in chronic obstructive
pulmonary disease (COPD)patients. COPD is char-
acterizedby apersistent and,usually, progressive air-
flow limitation and is associated with an enhanced
local inflammatory response. By 2030, COPD is pre-
dicted to become the fourth leading cause of death
worldwide, and therefore accounts for about 8% of
total deaths. Today, in addition to lung function im-
pairment, COPD is recognized as a systemic disease
with multiple comorbidities, such as osteoporosis,
cardiovascular disease, renal impairment, and
psychological disorders. In relation to the systemic
pathology of COPD the role of vitaminD has gener-
ated interest, as vitaminDdeficiency is often present
in patients with COPD,24 dependent on the severity
of COPD.25 Indeed, the prevalence of vitamin D
deficiency, defined as plasma 25(OH) D3 concen-
trations below 20 ng/ml (50 nmol/L), was 58% in a
cross-sectional study of 151COPDpatients entering
pulmonary rehabilitation during summer.26 In the
Bergen COPD Cohort Study, the prevalence of vi-
tamin D deficiency was indeed higher in the COPD
patients than in the control subjects, independent
of season, age, smoking, comorbidity, and body
mass index.27 Several potential explanations for the
increased risk of vitamin D deficiency in patients
with COPD include poor diet, less outdoor activity
and thus less exposure to sunlight, accelerated skin
aging due to smoking, renal dysfunction, and treat-
ment with corticosteroids. Vitamin D is related to
skeletal health in patients with COPD, and vitamin
D deficiency is associated with low bone mineral
density.26, 28 Additionally, low vitamin D has been
related to decreased exercise performance26, 29 and
exacerbation rate30 in COPD patients. And while
vitamin D concentration has been related to lung
function in the general population, the relation
between lung function and vitamin D concentra-
tion has yet to be investigated in COPD patients
only.
Rutten and colleagues performed a secondary
analysis of the publication by Romme et al.26 to
investigate whether there is an independent associa-
tion between lung function parameters and plasma
vitamin D levels in a group of 151 COPD patients
admitted for pulmonary rehabilitation at Ciro+.
Plasma 25(OH)D3 levels, body mass index (BMI;
weight in kg/(height in m)2), and lung function pa-
rameters (forced expiratory volume in 1s (FEV1),
forcedvital capacity (FVC), anddiffusing capacity of
the lung (DLCO)) were measured. The study group
comprised 57% males, with mean age 65 ± 9 years,
mean FEV1 47.2 ± 17.9% predicted, mean FVC
94.6 ± 20.6% predicted, and mean DLCO 53.2 ±
19.7% predicted; 58% of the patients were vitamin
D deficient (vitamin D concentration <20 ng/ml).
Pearson correlation coefficient showed significant
correlations between plasma vitamin D concentra-
tion and FEV1 (r = 0.31, P< 0.01), FVC (r = 0.29,
P < 0.01) and DLCO (r = 0.20, P = 0.01).
After stratification for vitamin D deficiency, the
correlations persisted only in the patients with vi-
tamin D deficiency: FEV1 (r = 0.37, P < 0.01;
Fig. 3, data are from an unpublished study), FVC
(r = 0.25, P < 0.01), and DLCO (r = 0.32,
Figure 3. Lung function and plasma vitamin D levels in a
group of 151 COPD patients. FEV1, forced expiratory volume
in 1 s. These data are from an unpublished secondary analysis
by Ruttan and colleagues.
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P = 0.02). Multivariate regression analyses re-
vealed that, after correction for age, gender,
and BMI, vitamin D concentration remained in-
dependently associated with FEV1 ( = 0.26,
P < 0.01) and DLCO ( = 0.25, P < 0.01), and
there was a trend for FVC (= 0.15, P< 0.08) in the
subjects with vitamin D deficiency. From their un-
published secondary analysis, Rutten and colleagues
conclude that there is evidence suggesting that vita-
min D plays a role in the lung pathology of patients
with COPD, which requires further investigation.
Impact of cholecalciferol repletion on
erythropoietin requirements in hemodialysis
patients
Lily Li (Cleveland Clinic Lerner College ofMedicine
of Case Western Reserve University and Mount
Sinai School of Medicine) presented pilot data
from a randomized control trial investigating
the impact of cholecalciferol repletion on ery-
thropoietin requirements in vitamin D–deficient
hemodialysis patients. Li mentioned that immune
cells contain the machinery needed to convert
25(OH)D3 to 1,25(OH)2D3, and that there is
evidence that this local production of 1,25(OH)2D3
has immunomodulatory properties. In a setting of
decreased 25(OH)D3, the absence of 1,25(OH)2D3
production may enhance local inflammation.
Among patients with end-stage renal disease
(ESRD) on hemodialysis, 25(OH)D3 deficiency is
common, reported at greater than 80%.32 ESRD
patients are commonly treated with 1,25(OH)2D3
for prevention of secondary hyperparathyroidism
and bone loss. However, 25(OH)D3 is rarely re-
pleted within this population, and the impact of
25(OH)D3 deficiency remains obscure. Anemia is
also associated with ERSD and is the result of re-
duced erythropoietin production due to kidney dis-
ease as well as iron deficiency and inflammation-
mediated abnormalities in iron metabolism. In
this population, anemia not only causes impaired
quality of life but also left ventricular hypertro-
phy, myocardial infarction, and increased mor-
tality. Patients with ESRD-associated anemia are
commonly treated with erythropoiesis-stimulating
agents (ESA), which are very effective in the major-
ity of the population. However, a subset of these pa-
tients develop erythropoietin hyporesponsiveness,
which is thought to be caused by inadequate iron
mobilization in the setting of inflammation, medi-
ated in part by hepcidin, a small molecule produced
by hepatocytes that is known to inhibit macrophage
iron release and intestinal iron absorption. Since
hepcidin production appears to be induced by IL-
6, and 25(OH)D3 has been shown to suppress IL-6
production in monocytes,33 Li’s group developed
the hypothesis that in hemodialysis patients defi-
ciency of 25(OH)D3, which is required for local
production of 1,25(OH)2D3 in immune cells, leads
to dysregulation of innate immunity and inflamma-
tion (e.g., enhanced IL-6 production), which alters
iron metabolism and contributes to erythropoietin
resistance.
They have initiated a randomized controlled
trial of 25(OH)D3 repletion in vitamin D–deficient
hemodialysis patients to evaluate efficacy and
safety and the effects on inflammation and ESA
requirements. Patients are given either no repletion
(standard of care) or 50,000 IU/week of cholecalcif-
erol for sixweeks, or until 25(OH)D3 levels exceeded
35 ng/mL, and 10,000 IU/week afterwards. Their
preliminary results show that 25(OH)D3 repletion
was both safe and effective, with 25(OH)D3 levels
increasing significantly in the treatment arm and no
patients experiencing hypercalcemia or other ad-
verse effects. In addition, patients in the treatment
arm exhibit a decrease in ESA requirement at six
months. Li and colleagues have isolated monocytes
frompatients and examined expression of a number
of genes related to vitamin D metabolism and
immune responses. Their observations include a
decrease in IL-6 expression following 25(OH)D3
repletion at six months. These preliminary data
indicate that 25(OH)D3 repletion treatment
is safe, effective, and may result in lower ESA
requirements, a result with significant economic
implications.
Translating epidemiological data into
policy and clinical applications
Vitamin D for diabetes
Anastassios G. Pittas (Tufts Medical Center) high-
lighted the potentially important role of vitamin
D in a variety of non-skeletal medical conditions,
including type 2 diabetes. To systemically appraise
the available evidence on the role of vitamin D in
diabetes, Pittas reviewed the original Bradford Hill
criteria, which have been subsequently modified
to include three general categories (mechanistic
studies, direct evidence, and parallel evidence),34
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and then applied these criteria to the available
evidence.
From a biological perspective, the hypothesis that
vitamin D may be a determinant of diabetes risk is
plausible, as both impaired insulin secretion and
action have been reported with vitamin D insuffi-
ciency. The effect of vitamin D may be direct, as
supported by the expression of the VDR and the lo-
cal productionof 1,25(OH)2D3 inpancreatic cells,
or indirect via its role in regulating calcium home-
ostasis and calcium flux through cell membranes.
Inhumans, the roleof vitaminD in type2diabetes
is suggested by a large number of cross-sectional
studies that have consistently found an inverse asso-
ciation between vitamin D status and prevalent hy-
perglycemia, including a reported seasonal variation
in the control of glycemia in patients with diabetes,
being worse in the winter when hypovitaminosis D
is more prevalent.35 In the majority of longitudinal
observational studies, lower vitamin D status is also
associated with increased risk of incident type 2 dia-
betes. In themost recent systematic review of obser-
vational studies, Song et al.36 reported a 38%relative
risk reduction in incident diabetes among individ-
uals with the highest versus the lowest category of
blood 25(OH)D3 concentration. In dose-response
analyses, the risk of type 2 diabetes was reduced by
4% for each 4 ng/mL increment in blood 25(OH)D3
concentration.
However, Pittas cautioned that one should re-
sist making inferences on the basis of observational
studies because of the possibility of confounding is-
sues, which may be especially true when assessing
vitamin D status, because while 25(OH)D3 concen-
tration is an excellentmarker of goodhealthmanyof
the variables that contribute to 25(OH)D3 concen-
tration (e.g., skin pigmentation, physical inactivity,
aging, unhealthy dietary patterns) are also risk fac-
tors for the development of diabetes. Therefore, evi-
dence from intervention studies—which is themost
direct evidence—is critically important before one
can conclude that vitamin D has a role in the pre-
vention or treatment of diabetes. The results from
small clinical trials and post hoc analyses of larger
trials on the effect of vitamin D supplementation
on diabetes-related parameters have been inconclu-
sive, although vitamin D appears to have beneficial
effects in persons at risk for diabetes.36–39 However,
no firm conclusions can be drawn from the available
intervention studies because of several limitations:
(1) nearly all studies were underpowered; (2) the
minority of studies were designed specifically for
glycemic outcomes; (3) most studies did not report
use of diabetesmedications at baseline or during the
study; (4) some trials used large infrequent doses of
vitamin D, which may be metabolized differently
compared to daily doses and may provide either no
benefit or result in an unfavorable benefit/risk ratio.
Pittas concluded that although the observation
studies strongly suggest an important role for
vitamin D in type 2 diabetes, and such a role is
biologically plausible, there is lack of evidence
from intervention studies to support the con-
tention that type 2 diabetes can be improved or
prevented by raising 25(OH)D3 concentration. On
numerous earlier occasions, encouraging findings
from observational studies were not confirmed
by well-designed clinical trials (e.g., hormone
replacement therapy, -carotene, vitamins C and E,
and folic acid) and prevailing clinical practice was
overturned. Therefore, confirmation of a potential
beneficial effect of vitamin D in type 2 diabetes
is needed in trials conducted in well-defined
populations (e.g., pre-diabetes and early diabetes)
specifically designed to test the compelling but yet
unprovenhypothesis that vitaminD status is a direct
contributor to the pathogenesis of type 2 diabetes.
Molecular aspects of the role of vitamin D in
muscle
Ricardo Boland (Universidad Nacional del Sur, Ar-
gentina) discussed molecular aspects of the role of
vitamin D in skeletal muscle health and function.
This is a topic of clinical significance because my-
opathy characterized by proximal muscle weakness
and atrophy is a common symptom in vitaminDde-
ficiency states.40 The loss of muscular strength and
a reduction in muscle mass increases the risk of falls
and leads to fractures. It has been reported that ad-
ministration of the hormonal vitamin Dmetabolite
1,25(OH)2D3 decreases the number of falls by im-
proving muscle strength in elderly subjects.41 Con-
sistent with this observation, there is evidence that
1,25(OH)2D3 regulates muscle growth and devel-
opment and contractility.40 Moreover, the presence
of the VDR in avian, murine, and human skeletal
muscle has been demonstrated.40, 42
As in other target cells, 1,25(OH)2D3 elicits long-
term and short-term responses in skeletal muscle
that involve genomic and non-genomic modes
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of actions, respectively. In the first, more classical
mechanism, the hormone stimulates muscle cell
proliferation and differentiation through nuclear
VDR-mediated gene transcription, expressed by
increased myoblast DNA synthesis followed by
the induction of muscle specific myosin- and
calcium-binding proteins. The non-genomic
effects of 1,25(OH)2D3 are involved in the fast
regulation of the calcium messenger system and
growth-related signal transduction pathways in
skeletal muscle cells. The hormone interacts with a
membrane receptor, which leads to stimulation of
adenylyl cyclase and phospholipases C, D, and A2
and activation ofMAPK cascades.43 Boland pointed
out that there is a wealth of evidence indicating that
1,25(OH)2D3 mainly acts in muscle through these
membrane-initiated events and that the VDR plays
a role in the activation of intracellular signaling
pathways.44
Boland then focused his presentation on the sig-
nal transduction mechanisms of 1,25(OH)2D3 in
skeletal muscle. 1,25(OH)2D3-induced transmem-
brane activation of adenylyl cyclase/cAMP/PKA
and PLC/DAG plus IP3/PKC regulates Ca2+ in-
flux mediated by voltage-dependent Ca2+ channels
(VDDC).43 Boland´s group showed that, in mus-
cle cells, the hormone also modulates Ca2+ in-
flux through SOC channels that are activated by
the PLC-mediated Ca2+ release from intracellu-
lar stores via IP3—a process known as capacita-
tive calcium entry (CCE).45 Boland discussed the
finding that 1,25(OH)2D3 rapidly induces reverse
translocation of the VDR from the nucleus to the
plasmamembranes.46 In accordancewith this obser-
vation, a complex is formed between the VDR and
TRCP3, an integral protein of capacitative Ca2+ en-
try, suggesting an association between both proteins
and a functional role of the VDR in 1,25(OH)2D3
activation of CCE. Further supporting this interpre-
tation, transfection with a VDR antisense oligonu-
cleotide inhibited Ca2+ influx through SOC chan-
nels. In some vertebrate systems, as in invertebrate
photoreceptor cells, TRP proteins have been shown
to interact with the PDZ domain–containing INAD
proteins, which serve as acceptors for a molecule
with a regulatory function, which Boland hypoth-
esized could be the VDR. Of additional mechanis-
tic importance, when muscle cells are treated with
1,25(OH)2D3 in the presence of a specific anti-
INAD antibody or transfected with an anti-INAD
antisense oligonucleotide, the hormone-dependent
CCE was almost totally suppressed.43, 45
These data enabled Boland and colleagues to
propose a non-genomic mechanism by which
1,25(OH)2D3 regulates intracellular Ca2+ levels in
skeletalmuscle cells: by acting onvoltage-dependent
channels via protein kinase–mediated phosphoryla-
tion and on SOC/TRCP3 channels through VDR-
joining membrane supramolecular complexes. Al-
terations in these mechanisms during vitamin D
deficiency states may account for skeletal muscle
weakness, in view of the key role that Ca2+ plays in
the regulation of contractility.
In addition, 1,25(OH)2D3 modulates growth-
related signal transduction pathways in skeletal
muscle cells. It has been established that the
hormone activates MAPKs (ERK1/2) and Akt.
Of note, the formation of complexes between
the VDR and Src is involved in the activation of
these pathways by the hormone.44, 45 Experimental
data demonstrates that 1,25(OH)2D3 induces the
translocation of activated ERK to the nucleus, where
it phosphorylates the transcriptional factors Elk
and CREB, which coregulate the expression of genes
that mediate mitogenic effects of the hormone.43
Akt is activated by 1,25(OH)2D3 through PI3K,
as the inhibitors Ly294002 and wortmannin block
the increase in its phosphorylation in response to
the hormone. Moreover, Akt mediates 1,25(OH)2
D3-induced differentiation of skeletal muscle
myoblasts to myotubes. With regard to the mech-
anism by which the hormone initiates its action
at the muscle cell plasma membrane, preliminary
work using MCD and siRNA technology has
shown that intact caveolae and caveolin-1 expres-
sion are involved in ERK1/2 and Akt activation by
1,25(OH)2D3 (C. Buitrago&R.Boland, submitted).
Boland concluded that the information described
contributes to the elucidation of the mechanisms
involved in the regulation of contractility and
myogenesis by 1,25(OH)2D3.
Vitamin D and physical and cognitive function
in older persons
Luigi Ferrucci (National Institute on Aging) dis-
cussed recent evidence linking vitamin D deficiency
to the pathogenesis and clinical progression of
chronic diseases highly prevalent in older persons.
In large population-based studies, low levels of vita-
minD predict loss ofmobility and disability in basic
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activities of daily living, independent of age and
other potential confounders.47 Based on these find-
ings, some gerontologists claim that vitamin D has
antiaging effects. Indeed, beyond its roles in bone
health and calcium homeostasis, vitamin D affects
many other physiological domains that are critically
modified by aging. Unfortunately, the question of
whether vitamin D prevents or slows aging cannot
be easily tested. In spite of the intuitive nature of
aging as a phenomenon, scientists have been unable
to agree on good measures of biological aging
because of great interindividual variability. Specific
phenotypic changes occur in almost all aging in-
dividuals: changes in body composition, imbalance
between production and utilization of energy, loss
of redundancy of the homeostatic network, and
loss of neurons and neuronal plasticity. Shifting
attention from aging to the aging phenotype, the
question of whether vitamin D affects major aging
phenotypes becomes more approachable.
Data from the literature can generate some
answers. Major changes in body composition that
occur with aging include a decline in lean bodymass
(mostly muscle) and increase in fat mass. There
is strong evidence that obesity is associated with
poor vitamin D status due to fat sequestration.48 In
fact, compared with the non-obese, higher doses of
vitamin D are required in obese individuals. Also,
regardless of dietary intake, weight loss results in
increased serum 25(OH)D3 levels in overweight or
obese women. However, some recent data suggest
that low vitamin D predicts an accelerated increase
in fat mass and incident obesity.
The importance of vitaminD formuscle has been
discussed at length. Interestingly, VDRexpression in
humanmuscle tissue decreases with aging, and vita-
min D level is strongly correlated with muscle qual-
ity and lowermuscle fat infiltration. Consistently, in
the Longitudinal Aging Study Amsterdam, low vita-
min D and high parathyroid hormone were strong,
independent risk factors for loss of muscle strength
andmusclemass (sarcopenia).49 Low vitaminD lev-
els also appear to be correlated with collagen de-
position and are related to arterial stiffness.50 The
role of vitamin D in energetics has been less thor-
oughly investigated. A recent study demonstrated
that vitamin D level correlates with maximal oxy-
gen consumption, and that supplementation of vi-
tamin D increases fitness in athletes. Interestingly,
a recent study found that VDRs are highly con-
centrated in the cristae of the mitochondria inner
membrane.51 The role of vitamin D in homeostatic
signaling is complex and pervasive. Vitamin D af-
fects several pathways related to inflammation and
cell proliferation, including inhibition of aromatase
(conversion from testosterone to estrogens), COX2,
prostaglandin receptor, NF-B, HIF-1 and VEGF,
and stimulation of IGFBP-3 and E-cadherin.52 In
addition, poor vitamin D status is a risk factor for
several autoimmune diseases, confirming the role of
this vitamin in immune function.
The role of vitamin D in neurologic function
and pathology has been studied from multiple per-
spectives. Vitamin D receptors are found in high
concentration in various areas of the brain. Low
vitamin D levels have been associated with accel-
erated cognitive decline in epidemiological stud-
ies, and low vitamin D dietary intake is associ-
ated with increased risk of Alzheimer’s disease and
depression.53, 54 Mechanisms suggested for this asso-
ciation include -amyloid formation/aggregation,
dysregulation of GABAergic activity and NMDA re-
ceptor, and increased calcium entry into neurons.
Overall, vitaminD appears to be implicated inmany
of the physiological and pathological changes that
occur with aging. Whether vitamin D supplemen-
tation may positively impact the aging process re-
mains unknown and will require further long-term
intervention studies.
Vitamin D dietary reference intakes
Daniel Bikle (University of California and VAMed-
ical Center, San Francisco) addressed the recent In-
stitute ofMedicine (IOM) recommendations for di-
etary intake of vitamin D and evaluated whether
they were sufficient in the context of emerging data
about the roles of vitamin D and the prevalence
of deficiency. Recommendations for the appropri-
ate amount of vitamin D to be taken for optimal
health—be it formusculoskeletal strength or for the
numerous nonskeletal presumptive benefits of vita-
min D—remain contentious. There is general con-
sensus that the earlier recommendation of 400 IU
of vitamin D/day was insufficient. Recently an IOM
expert panel established to formulate newguidelines
recommended that 600 IU/day would suffice for the
general public aged 1–70 years, with the dose in-
creased to 800 IU/day for those older than 70 years.
However, doses up to 4000 IU/day were consid-
ered safe.55 The task force compiling the Endocrine
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Society Clinical Practice Guidelines (ESCPG)
reached similar conclusions.56 Vitamin D status is
best assessed by the circulating levels of 25(OH)D3.
There is considerable variation among individuals
with regard to the serumlevel of 25(OH)D3 achieved
with a given dose of oral vitamin D, and it is the
serum level that counts with respect to biologic ef-
fect. The IOM expert panel concluded that most
Americans (97.5%) had adequate levels of vitamin
D, based on their conclusion that a 25(OH)D3 of 20
ng/mL or greater was sufficient, raising the question
of whether supplementation was even needed.
This conclusion was based on data from the
2001–2004 NHANES survey57 that primarily sam-
pled Caucasians, with limited sampling inNorthern
latitudes during the winter, the time and region
that people would most likely have lower vitamin
D levels. In that survey the average 25(OH)D3
level was over 20 ng/mL. People of color, especially
African-Americans, have substantially lower levels
of 25(OH)D3. Moreover, a number of studies have
shown that prevailing levels of 25(OH)D3, especially
in older subjects, the institutionalized, and in most
other countries, are well below those documented
in the NHANES survey.58 As parts of the aging
process, the skin becomes less able to make vitamin
D for a given amount of UVB exposure, the kidneys
become less able to produce the active metabolite
1,25(OH2)D3, and the intestine becomes less able
to respond to the 1,25(OH2)D3 with respect to
calcium absorption. Furthermore, the conclusion
by the IOMexpert panel, that 20 ng/mL is sufficient,
differs from that reached by the task force compiling
the ESCPG. This task force recommended a higher
target level, namely 30 ng/mL (75mM), andpointed
out that many individuals with a variety of condi-
tions, including obesity, dark skin, malabsorption,
renal failure, lactose intolerance, ingestion of certain
drugs, and the institutionalized, are likely not to
achieve adequate 25(OH)D levels by ingesting only
600 IU/day. If 30 ng/mL is deemed the optimal level
(and neither set of recommendations considers this
level unsafe), then the percent of Americans that
maintain the optimal level falls well below 50%.
A further complication in trying to achieve a given
level of 25(OH)D3 is that 25(OH)D3 assays have not
proven consistent, making decisions regarding sup-
plementation all the more difficult. This situation
is improving with the availability of standards from
the National Institute of Standards and Technol-
ogy. However, those assays relying on binding pro-
teins or antibodies tend to report lower 25(OH)D
levels than assays employing chromatography/mass
spectroscopy.59 Moreover, the latter can separately
determine 25(OH)D2 and 25(OH)D3 levels, as well
as the level of 3-epimer of 25(OH)D3, capabilities
that are lacking in the binding protein/antibody as-
says. While the clinical significance of these differ-
ences in assays is not clear, they do complicate deci-
sion making when a fixed target level of 25(OH)D3
is being sought. In practical terms, young, healthy,
light-skinned individuals with good diets that in-
clude dairy products and who have adequate expo-
sure to sunlight are not likely to be vitamin D defi-
cient or need to be tested. Individuals of color, the
aged, thosewith gastrointestinal disorders, the insti-
tutionalized, and those with poor nutrition should
be tested and treated appropriately to achieve a
25(OH)D3 level of at least 20 ng/mL, or perhaps
closer to 30 ng/mL. Daily doses appear to be safer
and more efficacious than large doses administered
once or twice a year.
Conclusions
The conference “Vitamin D: Beyond Bone” explo-
red a considerable range of functions for vitamin
D and potential therapeutic implications outside
of calcium homeostasis and bone health, highlight-
ing the increased understanding of vitamin D, as
well as how much is yet to be learned. The scope
of vitamin D research and its therapeutic possi-
bilities, as presented by researchers across many
different disciplines, generated enthusiasm tem-
pered with some skepticism. Continuing research
is needed to better understand the relationships be-
tween vitamin D and extraskeletal health and to
determine the optimal dose of vitamin D for indi-
viduals based on age, health conditions, and other
factors.
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